Several studies have shown that BCYRN1 expression is significantly increased in a variety of tumors and has been shown to be a biomarker for these tumors, including colorectal cancer [32], hepatocellular carcinoma [33], bladder cancer [34] and non-small-cell lung cancer [35]. This evidence concerns the gene BCYRN1 and urinary bladder carcinoma.